drugset
drugset / Trial / NCT04840927

A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

NCT04840927 ↗

Phase 1 Withdrawn Eisai Inc.
RandomizedParallel-groupOpen-labelOther

Summary

The primary purpose of this study is to evaluate the pharmacokinetic (PK) profile of E7386 following oral administration of E7386 enteric coated TR prototype tablet formulations (TR1, TR2 and optional TR3) and to evaluate the relative bioavailability of E7386 TR tablets compared to E7386 IR reference tablet.

Timeline

Start
2021-04-09
Primary completion
2023-05-17
Completion
2023-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject E7386 Small molecule 40 mg Oral

Indications

No indication recorded.